【佳學(xué)基因檢測】CRISPR/Cas9 引導(dǎo)的表觀遺傳調(diào)控對神經(jīng)精神疾病的潛在治療意義

靶向藥一個月費(fèi)用排序

閱讀神經(jīng)系統(tǒng)啟動預(yù)防及反復(fù)抑制基因檢測聽到《Curr Top Med Chem》在.?2021;21(10):878-894.發(fā)表了一篇題目為《CRISPR/Cas9 引導(dǎo)的表觀遺傳調(diào)控對神經(jīng)精神疾病的潛在治療意義》腫瘤靶向藥物治療基因檢測臨床研究文章。該研究由Desh D Singh, Ravi Verma, Piyush Parimoo, Ashish Sahu, Vikram Kumar, Era Upadhyay, Dharmendra K Yadav等完成。促進(jìn)了腫瘤的正確治療與個性化用藥的發(fā)展，進(jìn)一步強(qiáng)調(diào)了基因信息檢測與分析的重要性。

精神科神經(jīng)科致病基因及正確治療臨床研究內(nèi)容關(guān)鍵詞：

GWAS,動物模型,雙極,會聚功能基因組學(xué),基因表達(dá)

精神科心理科疾病用藥指導(dǎo)基因檢測臨床應(yīng)用結(jié)果

腦功能活動受遺傳和表觀遺傳因素的幾種機(jī)制的調(diào)節(jié)，例如組蛋白建模、DNA 甲基化和非編碼 RNA。這些調(diào)節(jié)機(jī)制的改變會影響導(dǎo)致神經(jīng)精神疾病 (ND) 的神經(jīng)元的正常發(fā)育。然而，需要分析與分子機(jī)制相關(guān)的神經(jīng)精神疾病的功能意義，以在患者的早期診斷和治療中帶來治療進(jìn)展。 CRISPR/Cas 9（Clustered Regularly Interspaced Short Palindromic Repeats）基因組編輯工具同時有效改變了多個基因組和表觀基因組操作目標(biāo)。本綜述討論了在 ND 的分子機(jī)制中使用 CRISPR/Cas 9 工具作為一種治療方法來克服由遺傳和表觀遺傳異常引起的 ND 的可能性。表觀遺傳規(guī)律；基因編輯；神經(jīng)元發(fā)育；神經(jīng)精神疾?。恢委煈?yīng)用。轉(zhuǎn)錄因子。

神經(jīng)及精神疾病及其并發(fā)征、合并征國際數(shù)據(jù)庫描述：

Brain function activity is regulated by several mechanisms of genetic and epigenetic factors such as histone modelling, DNA methylation, and non-coding RNA. Alterations in these regulatory mechanisms affect the normal development of neurons that causes Neuropsychiatric Disorders (ND). However, it is required to analyse the functional significance of neuropsychiatric disorders associated with a molecular mechanism to bring about therapeutic advances in early diagnosis and treatment of the patients. The CRISPR/Cas 9 (Clustered Regularly Interspaced Short Palindromic Repeats) genome editing tools have revolutionized multiple genome and epigenome manipulation targets the same time. This review discussed the possibilities of using CRISPR/Cas 9 tools during molecular mechanism in the ND as a therapeutic approach to overcome ND that is caused due to genetic and epigenetic abnormalities.Keywords:?CRISPR/Cas9; Epigenetic regulations; Gene editing; Neuronal development; Neuropsychiatric Disorders; Therapeutic applications.; Transcription factor.

• 上一篇：【佳學(xué)基因檢測】CRISPR/dCas9 作為神經(jīng)發(fā)育障礙的治療方法：與傳統(tǒng)策略相比的創(chuàng)新和局限性
• 下一篇：【佳學(xué)基因檢測】表觀基因組、4D核組和下一代神經(jīng)精神藥物基因組學(xué)

• 收藏
• 挑錯
• 推薦
• 打印